Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM).
Teresa M. Petrella
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Catalin Liviu Dragos Mihalcioiu
No relevant relationships to disclose
Elaine McWhirter
No relevant relationships to disclose
Karl Belanger
No relevant relationships to disclose
Kerry J. Savage
No relevant relationships to disclose
Xinni Song
No relevant relationships to disclose
Omid Hamid
No relevant relationships to disclose
Tina Cheng
No relevant relationships to disclose
Mary L. Davis
No relevant relationships to disclose
Christopher W Lee
No relevant relationships to disclose
Alan Spatz
No relevant relationships to disclose
Jose Gerard Monzon
No relevant relationships to disclose
Linda Hagerman
No relevant relationships to disclose
Bingshu E Chen
No relevant relationships to disclose
Janet Dancey
No relevant relationships to disclose